After five years of building and advancing a pharmaceutical portfolio that proved difficult to fund, Christopher Moreau decided it was time to find a new cash flow-focused avenue into the healthcare sector that could provide explosive returns to investors. The result is Gray Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0), a rebranded and refocused company with a singular mission: to build the first dedicated brain PET scan diagnostic network in the United States, starting with a flagship clinic in Florida opening in September.
“When new investors come to the story, they will discover a new, exciting and compelling story,” says Moreau, the company’s CEO. “This is really a new beginning and a new direction.”
Algernon Health’s rebrand reflects both a change in identity and a change in strategy. Drug repurposing, the company’s original focus, is capital-intensive by nature, and access to that capital proved elusive for a CSE-listed company that can’t access U.S. institutional funds because it can’t buy or invest in CSE-listed stocks. Moreau concluded that nuclear medicine and neuroimaging offered a more accessible path to building a sustainable, cash-generating healthcare business. Whether he is right remains to be seen, but the first clinic will offer an early test.
Why the brain diagnosis and why now
The move to neuroimaging was not arbitrary. Several converging developments made the sector look attractive. First, the FDA approved two antibody therapies for Alzheimer’s disease that target amyloid plaque buildup in the brain, but access to either treatment requires diagnostic confirmation through a brain PET scan or lumbar puncture. That requirement has created a surge in demand among the approximately seven million Americans currently living with Alzheimer’s. Second, Medicare and Medicaid eliminated a previous, once-in-a-lifetime limit on brain PET scans. Third, the FDA approved a new PET scanner dedicated to the brain that Gray Matters can access through a partnership with Catalyst Med Tech.
Meanwhile, traditional hospitals and imaging centers have long deprioritized neuroimaging. Standard PET-CT systems are primarily configured for abdominal cancer and cardiac diagnosis and theranostic imaging; Currently, only about 10% of examinations are neurological. Neuroscanners take longer, generating less revenue for facilities with competing priorities. The result, Moreau again, is a growing gap between demand and available capacity.
A PET scanner that changes the patient experience
At the heart of the Gray Matters model is technology that looks considerably different from a conventional PET/CT machine. Traditional systems weigh up to 11,000 pounds, cost between $3 million and $5 million, and require hundreds of thousands more in installation and protection of walls and doors. They also require patients to lie on a narrow table and move toward a large halo structure, which can be distressing for a healthy person, not to mention patients suffering from memory loss or cognitive impairment. Many patients with neurodegenerative diseases are older and movement of the scanner table toward the scanner can also cause dizziness and claustrophobic events.
The scanner Gray Matters has partnered on costs about $850,000, plugs into the wall and requires only about $10,000 in lead protection. Instead of lying down and entering a tunnel, patients sit upright in a chair while the scanner moves around them, reducing claustrophobia and dizziness. Because the system does not require a CT component, patients receive approximately 25% less radiation than with a conventional scan.
The economy, according to management’s projections, is also favorable. After isotope costs, the company would earn net revenue of approximately $2,100 per scan, with revenue of approximately $4,500 covered by Medicare, Medicaid, and private insurance. At those numbers, breaking even would require only about 1.6 scans per day, although translating initial projections into a constant patient volume is precisely the execution challenge that the first clinic will need to demonstrate.
NovaScan debuts in Florida
Gray Matters’ first NovaScan clinic will open within the medical offices of HCA Florida University Hospital in Davie, which currently outsources all PET imaging for its neurology patients. The clinic will be integrated directly into the hospital property, with a space already built and adapted to the needs of the company. Gray Matters will also establish its corporate headquarters there.
Each clinic is designed to operate efficiently: approximately 1,800 square feet, two main staff members, including a certified nuclear medicine technologist and an administrator, and a concierge-style model built around older patients who make up the majority of the patient base.
Three additional Florida locations are planned for the second quarter of 2027. Medical outreach is already underway, targeting neurologists, geriatricians, psychiatrists and primary care physicians within an approximately 90-minute radius of each clinic. A marketing alliance with GE Healthcare will help introduce NovaScan into established referral networks, while a partnership with American Radiology encompassing 80 neuro-disease radiologists, who will read NovaScan images and provide a diagnosis, supports the model’s clinical credibility.
A different investment thesis
For investors, the Gray Matters story represents a significant shift in what they are being asked to bet. Drug development companies continually raise capital to fund trials that can take years to reach a commercial milestone. The NovaScan model is based on operating cash flow from day one.
Scaling the company’s stated ambition of several hundred locations across the country will require consistent execution, sustained access to isotope supply, insurance credentials in multiple markets, and capital for expansion. The company’s shares are currently near all-time lows, which Moreau sees as a potential entry point ahead of what he hopes will be a demonstrable trading milestone before the end of the year.
The CEO is candid about the journey to get here. “Sometimes you have to drag people through the bushes a little bit before they understand all the important critical details of a new business plan,” he said. “We think we have a better mousetrap and to understand that you need to explain how the current standard of care works and how we think it’s falling short and therein lies the opportunity.”
The first clinic will determine if the new one deserves the thorns.
Your Trusted Source for Accurate and Timely Updates!
Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
